About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
Our Science
  • Romidepsin (Histone Deacetylase Inhibitor)

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Proposed Mechanism of Action

    The epigenetic modifier romidepsin is a potent class 1 selective histone deacetylase inhibitor.1-2 Altered expression, dysregulation, and mutations of histone deacetylase (HDAC) genes have been implicated in tumor development in cells of various cancers.3,4 In preclinical studies, HDAC inhibitors, such as romidepsin, prevent HDACs from removing acetyl groups, both allowing DNA to remain transcriptionally active (eg, tumor suppressor genes) and maintaining the acetylation of non-histone proteins (eg, genes involved in cell growth and differentiation).1,3,5 The downstream anti-cancer effects of HDAC inhibitors potentially include interference with cell cycle and mitosis, decreased cell motility, decreased angiogenesis, cell differentiation, and cell death.1,3,4,6

    Romidepsin Hypothesized Mechanism of Action

    Binding of romidepsin to HDACs has been hypothesized to result in various downstream anti-cancer effects, including in lymphoma.

    Romidepsin by Disease State

    Romidepsin in Lymphoma

    Post Approval Research
    Cutaneous T-cell lymphoma (US)

    Post Approval Research
    Peripheral T-cell lymphoma: Relapsed/refractory

    Phase 3
    Peripheral T-cell lymphoma: First-line

    View Trials Investigating Romidepsin in Lymphoma
    View Rationale for Clinical Development

    Preclinical work showing anti-tumor properties of romidepsin provides support for clinical studies of this compound. Romidepsin is being investigated in a phase III study in combination with chemotherapy vs chemotherapy alone in patients with previously untreated PTCL.

    View Related Pathways

    References

    1. Bolden JE, et al. Nat Rev Drug Discov. 2006;5:769-784. PMID: 16955068
    2. Bradner JE, et al. Nat Chem Biol. 2010;6:238-243. PMID: 20139990
    3. New M, et al. Mol Oncol. 2012;6:637-656. PMID: 23141799
    4. Marsoni S, et al. Epigenetics. 2008;3:164-171. PMID: 18487953
    5. Ho E, et al. J Nutr. 2009;139:2393-2396. PMID: 19812222
    6. Khan O, La Thangue NB. Immunol Cell Biol. 2012;90:85-94. PMID: 22124371